Randomized elamipretide trial results
The Forzinity label says its randomized trial was not superior to placebo on the primary six-minute-walk and fatigue endpoints. This finding concerns Forzinity, not the supplier's SS-31 (Elamipretide) Pen. Forzinity prescribing information.
Forzinity's accelerated approval was based on knee-extensor muscle strength, with continued approval potentially dependent on verification of clinical benefit. Knee-extensor strength, the six-minute walk and fatigue are different endpoints in the label's evidence account. Forzinity prescribing information.
Forzinity US indication and approval endpoint
Forzinity is an elamipretide product with an initial US approval date of September 19, 2025. Its label identifies a mitochondrial cardiolipin binder and an indication to improve muscle strength in patients with Barth syndrome weighing at least 30 kg. FDA Forzinity approval snapshot, Forzinity prescribing information.
The supplier's SS-31 (Elamipretide) Pen is not authenticated or approved by that product-specific decision. Nor does the US label establish Thai approval. A shared substance name cannot turn the restricted Forzinity indication into a general effect attributed to a catalogue pen. FDA Forzinity approval snapshot, Forzinity prescribing information.
Forzinity side effects and SS-31 pen amounts
Injection-site reactions are the most common adverse reactions identified by the Forzinity label. That is a finding about the medicine discussed in the label. It does not measure reaction frequency in the supplier pen or establish a safety profile for it. Forzinity prescribing information.
The pen's 10mg / 50mg options and the separate SS-31 vial are catalogue presentation fields. They are not concentrations or clinical instructions, and they do not establish an equivalence to the Forzinity formulation.
